Long-Term Study on Safety and Effectiveness of Biological Treatments for Inflammatory Joint Diseases
Led by Diakonhjemmet Hospital · Updated on 2022-08-23
15000
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the long-term safety and effectiveness of biological disease modifying anti-rheumatic drugs DMARDs in people with inflammatory joint diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other related conditions. This observational study aims to measure disease activity, quality of life, joint function, joint damage, and work productivity, as well as the cost-effectiveness and predictors of treatment outcomes. The study also focuses on ensuring systematic follow-up of patients treated with these therapies.
The study involves regular visits starting at the beginning of a new biological DMARD or kinase inhibitor treatment, with follow-up visits at 3, 6, and 12 months, then every 12 months thereafter. Each visit includes clinical assessments, patient questionnaires, and laboratory tests including blood samples collected for biobank storage at baseline and 3 months. Serious adverse events are systematically recorded, with additional information collected through linkage to other registries.
Participants will be involved in ongoing monitoring through clinical evaluations, patient-reported outcomes, and laboratory tests such as blood inflammatory markers. Various disease activity scores and questionnaires are used at multiple time points up to five years to track treatment effects and safety. The study is designed to provide long-term data on the use of biological DMARDs in real-world clinical practice with continued follow-up and safety monitoring.
CONDITIONS
Brief Title
The Norwegian Antirheumatic Drug Register
Research Team
E
Eirik K Kristianslund, MD, PhD
E
Espen A Haavardsholm, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, adult juvenile idiopathic arthritis, undifferentiated arthritis, or any other inflammatory arthritis
Clinical indication to start a new biological disease modifying anti-rheumatic drug or kinase inhibitor treatment
You will not qualify if you...
Unwillingness or inability to provide written informed consent
Psychiatric or mental disorders, alcohol or substance abuse, language barriers, or other factors preventing adherence to the study protocol
Participation in blinded randomized clinical trials or other studies incompatible with this study protocol
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 10 years
Participants are monitored through scheduled visits including clinical assessments, patient-reported outcomes, and blood sample collection to evaluate the long-term safety and effectiveness of disease modifying therapies.
Visits at baseline, 3, 6, 9, 12, 18, 24, 36, 48, 60 months and annually thereafter
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Pilot Evaluation of a Patient-Centered Care Approach for Older African American Adults with Cardiovascular and Chronic Conditions at Cooper Green Mercy Health Services
Study of Blood Redox Status and Disease Progression in Adults with Autoimmune Rheumatic Diseases
Long-Term Study on Safety and Effectiveness of Biological Treatments for Inflammatory Joint Diseases
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.
Johanna Elin Gehin, Guro Løvik Goll, David John Warren...
How to score the wrist joint by ultrasound: exploration of the most sensitive joint assessment during follow-up of early or established rheumatoid arthritis.
Yusuke Yoshida, Hilde Berner Hammer, Joseph Sexton...